View More Recent Stories
-
Viking Therapeutics (VKTX) call put ratio 4 calls to 1 put with focus on August 23 weekly 66 and 69 calls
-
Viking Therapeutics (VKTX) call put ratio 3.9 calls to 1 put with focus on November 70 calls
-
RBC's biotech survey shows investors more bearish vs. last time
-
Options with decreasing option implied volatility: GME VKTX TSLL ALGN QS ENPH SPOT HE HOG VRT
-
After-hours movers: Chipotle Mexican Grill, Ford, IBM, Edwards Lifesciences, and more
-
Viking Therapeutics (VKTX) to advance VK2735 into Phase 3 program for obesity
-
Viking Therapeutics (VKTX) Tops Q2 EPS by 6c
-
Viking Therapeutics (VKTX) call put ratio calls to 1 put with focus on August 65 calls
-
Viking Therapeutics (VKTX) 30-day option implied volatility above 100 after Roche reports weight loss pill data
-
Novo Nordisk (NVO), Others Decline After Pfizer (PFE) Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
-
BTIG Out Positive on Viking Therapeutic (VKTX), 'favorable catalyst set up for VKTX headed into 2H24'
-
Viking Therapeutics (VKTX) 30-day option implied volatility is at 109; compared to its 52-week range of 51 to 234 as share price up 3.6% to $52.60. Call put ratio 14.3 calls to 1 put with focus on Jul
-
Morgan Stanley Starts Viking Therapeutic (VKTX) at Overweight
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists
-
Viking Therapeutics (VKTX) option IV below 100
-
Viking Therapeutics (VKTX) call put ratio 2.2 calls to 1 put on flat IV
-
Here are Oppenheimer’s best Smidcap ideas
